GlassScriptPhysician profile
Fataneh Amidi
NPI 1134357981
$2,221.90
in general payments reported to CMS, 2019-2025
26 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $60.37 · 2021: $74.40 · 2022: $336 · 2023: $509 · 2024: $646 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $421.42 | 2023-2024 | Bodyguardian |
| Sage Therapeutics, LLC | $270.70 | 2024-2025 | Zurzuvae |
| Organon LLC | $251.45 | 2021-2025 | Nexplanon |
| Abbvie INC. | $227.72 | 2019-2023 | Lo Loestrin Fe |
| Baxter Healthcare | $97.31 | 2020-2024 | Perclot |
| Hologic Sales and Service, LLC | $93.31 | 2024-2025 | Thinprep 2000 Processor, Aptima, Novasure |
| Aspira Women'S Health INC | $92.71 | 2022-2024 | Ova1 |
| Mayne Pharma Commercial LLC | $88.29 | 2022-2023 | |
| Intuitive Surgical, INC. | $79.88 | 2019 | |
| Astellas Pharma US INC | $70.80 | 2023-2024 | Veozah |
| Covidien LP | $55.06 | 2019 | |
| Gilead Sciences, INC. | $54.03 | 2025 | |
| Shield Therapeutics INC | $51.95 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $47.52 | 2024 | |
| Sumitomo Pharma America, INC. | $46.18 | 2024 | Myfembree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $43.56 | 2022-2023 | Slynd |
| Evofem Biosciences, INC. | $38.30 | 2022-2025 | Phexxi, Solosec, Phexx |
| Minerva Surgical, INC | $29.79 | 2023 | |
| Roche Diagnostics Corporation | $24.17 | 2019 | |
| Allergan, INC. | $23.71 | 2020 | |
| Agile Therapeutics, INC. | $23.33 | 2023 | Twirla |
| Ethicon US, LLC | $19.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.40 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $17.73 | 2022 | |
| Medicem INC. | $17.56 | 2021 | |
| Meditrina | $16.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fataneh Amidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.